Comparative Effectiveness of Upadacitinib Versus Ustekinumab in Ulcerative Colitis Patients With Prior Tumor Necrosis Factor Inhibitor Exposure
In patients with ulcerative colitis and prior anti-TNF exposure, upadacitinib was associated with lower oral corticosteroid use than ustekinumab over 1 year, with no significant differences in rates of colectomy, ED visits or hospitalizations. These findings suggest a potanial higher effectiveness of upadacitinib compared with ustekinumab and may help inform treatment selection in this population.
Authors
- Khaled Elfert (ORCID: https://orcid.org/0000-0001-5554-6252)
- Kanwarpreet Tandon (ORCID: https://orcid.org/0000-0003-0941-1589)
- Jennifer Hadam-Veverka
- Omar Alkasabrah (ORCID: https://orcid.org/0009-0000-9767-7226)
- Muhammad M. Elsharkawy
- Mohamed H. Eldesouki
- Mohamed Elzayat
- Mouhand Mahmoud
Institutions
- West Virginia University (US)
- New York Medical College (US)
- CVS Health (United States) (US)
- Mayo Clinic in Arizona (US)
- Saint Michael's Medical Center (US)
- Alexandria University (EG)
Publication Details
- Journal
- Journal of Clinical Gastroenterology
- Published
- 2026-03-16
- DOI
- https://doi.org/10.1097/mcg.0000000000002354
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00